Tvardi Therapeutics is trading at $1.19, up 11.79%, on September 25, 2026, following preclinical findings that oral TTI-101 prevented polyps and adenocarcinomas in mice. - September 24 results found oral TTI-101 reached roughly eight times higher concentrations in colon tissue than plasma. - The findings were published in the International Journal of Molecular Sciences; the company described this as the fourth preclinical colitis model showing biological activity. - Current volume data was unavailable in the supplied context or source.